Startups channel feed

Car­olyn Bertozzi-found­ed Ly­cia Ther­a­peu­tics rais­es $106M to en­ter the clin­ic

12 months ago
Financing

'At­tack JAK': Ajax se­cures $95M to test new JAK2 in­hibitor af­ter in­dus­try's string of myelofi­bro­sis deals

12 months ago
Financing

Sci­en­tists and star­tups re­veal new gene in­ser­tion tech­niques, though much re­mains be­hind closed doors: #AS­GCT24

Last year
R&D
Cell/Gene Tx

Ace­lyrin's found­ing CEO steps down, com­pa­ny scraps earn­ings call

Last year
People

In­fec­tious dis­ease biotech Blue­jay rais­es $182M for he­pati­tis tri­als

Last year
Financing

At­tovia reels in $105M from crossover in­vestors to run mul­ti­ple tri­als of I&I bi­o­log­ics

Last year
Financing

No­vo Nordisk sees more to GLP-1's fu­ture in $600M pact with Flag­ship's Metaphore

Last year
Deals

Aard­vark nabs $85M to tar­get hunger, not ap­petite, as it eyes 2026 NDA fil­ing

Last year
Financing

Os­car is wind­ing down its small em­ploy­er health plans with Cigna

Last year
Health Tech

Ex­clu­sive: En­gi­neered B cell ther­a­py start­up Walk­ing Fish shuts down

Last year
People

Lab­Cen­tral helped cre­ate 6,300 jobs and 19 IPOs. Amid a slump, de­mand for lab space has slowed

Last year

As dig­i­tal health uni­corns are pres­sured to do more with less, Tran­scar­ent gets a fresh $126M

Last year
Health Tech

Flag­ship com­mits $50M to new start­up that scours vi­ral pro­teins for new drugs

Last year
Financing

As­traZeneca-al­lied Ec­co­gene tar­gets ear­ly 2025 Nas­daq IPO with mul­ti­ple NASH can­di­dates

Last year
Financing

Ex­clu­sive: New York biotech de­buts with $16M to find new ways to make sol­id can­cer cell ther­a­pies

Last year
Financing
Cell/Gene Tx

No­var­tis makes a $1B ra­dio­phar­ma deal, buy­ing Mar­i­ana On­col­o­gy

Last year
Deals
Pharma

Bridge­Bio spins out on­col­o­gy unit with $200M in back­ing for RAS as­sets

Last year
Financing
Deals

A once-pub­lic psy­che­del­ic biotech reemerges with $103M from MPM and No­vo Hold­ings

Last year
Financing

Ex­clu­sive: Spark co-founder launch­es new CNS gene ther­a­py biotech with $54M

Last year
Financing
Cell/Gene Tx

Bris­tol My­ers buys in­to Reper­toire's au­toim­mune vac­cines, giv­ing new life to Flag­ship start­up

Last year
Deals
Pharma

En­deav­or Bio­Med­i­cines snags $132M for Phase 2 fi­bro­sis drug, ADC can­di­date

Last year
Financing

Flag­ship’s gene edit­ing start­up Tessera cuts jobs as it shifts re­sources to clin­ic

Last year
People
Cell/Gene Tx

Ex­clu­sive: Marc Tessier-Lav­i­gne on leav­ing Stan­ford and join­ing biotech’s new AI mega-start­up

Last year
People
AI

In­cyte inks $750M deal for im­mune and neu­ro biotech Escient

Last year
Deals
First page Previous page 15161718192021 Next page Last page
A service from the Financial Times